Journal of Inherited Metabolic Disease

, Volume 36, Issue 3, pp 499–512

Retroviral-vector-mediated gene therapy to mucopolysaccharidosis I mice improves sensorimotor impairments and other behavioral deficits

Authors

  • Guilherme Baldo
    • Department of Internal MedicineWashington University School of Medicine
    • Gene Therapy CenterHospital de Clinicas de Porto Alegre
  • David F. Wozniak
    • Department of PsychiatryWashington University School of Medicine
  • Kevin K. Ohlemiller
    • Department of OtolaryngologyWashington University School of Medicine
  • Yanming Zhang
    • Department of Internal MedicineWashington University School of Medicine
  • Roberto Giugliani
    • Gene Therapy CenterHospital de Clinicas de Porto Alegre
    • Department of Internal MedicineWashington University School of Medicine
    • Department of Biochemistry and Molecular BiophysicsWashington University School of Medicine
Original Article

DOI: 10.1007/s10545-012-9530-x

Cite this article as:
Baldo, G., Wozniak, D.F., Ohlemiller, K.K. et al. J Inherit Metab Dis (2013) 36: 499. doi:10.1007/s10545-012-9530-x

Abstract

Mucopolysaccharidosis I (MPS I) is a lysosomal storage disease due to α-L-iduronidase (IDUA) deficiency that results in the accumulation of glycosaminoglycans (GAG). Systemic gene therapy to MPS I mice can reduce lysosomal storage in the brain, but few data are available regarding the effect upon behavioral function. We investigated the effect of gene therapy with a long-terminal-repeat (LTR)-intact retroviral vector or a self-inactivating (SIN) vector on behavioral function in MPS I mice. The LTR vector was injected intravenously to 6-week-old MPS I mice, and the SIN vector was given to neonatal or 6-week-old mice. Adult-LTR, neonatal-SIN, and adult-SIN-treated mice achieved serum IDUA activity of 235 ± 20 (84-fold normal), 127 ± 10, and 71 ± 7 U/ml, respectively. All groups had reduction in histochemical evidence of lysosomal storage in the brain, with the adult-LTR group showing the best response, while adult-LTR mice had reductions in lysosomal storage in the cristae of the vestibular system. Behavioral evaluation was performed at 8 months. Untreated MPS I mice had a markedly reduced ability to hold onto an inverted screen or climb down a pole. LTR-vector-treated mice had marked improvements on both of these tests, whereas neonatal-SIN mice showed improvement in the pole test. We conclude that both vectors can reduce brain disease in MPS I mice, with the LTR vector achieving higher serum IDUA levels and better correction. Vestibular abnormalities may contribute to mobility problems in patients with MPS I, and gene therapy may reduce symptoms.

Supplementary material

10545_2012_9530_MOESM1_ESM.pdf (2.2 mb)
ESM 1(PDF 2,303 kb)

Copyright information

© SSIEM and Springer 2012